Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogenerics Bill Differs From ANDA System In Exclusivity, Patent Listing

Executive Summary

Recently introduced follow-on biologics legislation has several characteristics that make it distinct from the current approval pathway for generic drug

You may also be interested in...



FDA Follow-On Biologics Letter Creates Hurdle For Obama Administration

A letter from FDA to the House Energy & Commerce Committee could delay any plans the incoming Obama Administration may have in moving forward with an abbreviated pathway to approve follow-on biologics

FDA Follow-On Biologics Letter Creates Hurdle For Obama Administration

A letter from FDA to the House Energy & Commerce Committee could delay any plans the incoming Obama Administration may have in moving forward with an abbreviated pathway to approve follow-on biologics

Follow-On Biologics Bill Could Be Shaped By Waxman/Dingell Fight For House Commerce Cmte.

Chairmanship would give Waxman more leverage to place regulatory flexibility into the biosimilars approval pathway.

Related Content

UsernamePublicRestriction

Register

PS047637

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel